Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab.
Id1 Expression Promotes T Regulatory Cell Differentiation by Facilitating TCR Costimulation.
Elevated Expression of the Cerebrospinal Fluid Disease Markers Chromogranin A and Clusterin in Astrocytes of Multiple Sclerosis White Matter Lesions.
Distraction adds to the cognitive burden in multiple sclerosis.
Excitotoxic mechanisms of ischemic injury in myelinated white matter.
[Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain].
Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosis.
Rhythmic auditory cueing to improve walking in patients with neurological conditions other than Parkinson's disease - what is the evidence?
Targeting intracerebral inflammation in multiple sclerosis: is it feasible?
Validation and interpretation of the Dutch version of the Multiple Sclerosis Neuropsychological Screening Questionnaire.
Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations.
Review of MR elastography applications and recent developments.
Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis.
Unemployment in multiple sclerosis (MS): utility of the MS Functional Composite and cognitive testing.
The therapeutic value of yoga in neurological disorders.
UCSF Neuroimmunology Research Seminar
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon Beta-1a in patients with multiple sclerosis.
Using a highly abbreviated California Verbal Learning Test-II to detect verbal memory deficits.
Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence.
Stress, Depression and Antidepressant Treatment Options in Patients Suffering from Multiple Sclerosis.
Animal models of multiple sclerosis: the good, the bad and the bottom line.
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod.
Development and assessment of a website presenting evidence-based information for people with multiple sclerosis: the IN-DEEP project.
Pages
« first
‹ previous
…
211
212
213
214
215
216
217
218
219
…
next ›
last »